Iron-deficient diet reduces atherosclerotic lesions in ApoE-deficient mice

Circulation

Volumn 99, Issue 9, 1999, Pages 1222-1229

  Lee, Tzong Shyuan ^a   Shiao, Ming Shi ^b   Pan, Ching Chien ^a   Chau, Lee Young ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Atherosclerosis; Iron; Lipoproteins; Oxygen

Indexed keywords

AUTOANTIBODY; IRON; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IRON DEFICIENCY; IRON INTAKE; IRON KINETICS; LIPID OXIDATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033537671     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.9.1222     Document Type: Article

References (36)

1. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1:1293-1294.
2. Badylak SF, Simmons A, Turek J, Babbs CF. Protection from reperfusion injury in the isolated rat heart by postischaemic deferoxamine and oxypurinol administration. Cardiovasc Res. 1987;21:500-506.
3. Bolli KR, Patel BS, Zhu X-X, O'Neill PG, Hartley CJ, Charlat ML, Roberts R. The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction. Am J Physiol. 1987;253:H1372-H1380.
4. Reddy BR, Kloner RA, Przyklenk K. Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury. Free Radic Biol Med. 1989;7:45-52.
5. Van der Kraaij AMM, Van Eijk HG, Koster JF. Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation. 1989;80:158-164.
6. Leshefsky EJ, Repine JE, Horwitz LD. Deferoxamine pretreatment reduces canine infarct size and oxidative injury. J Pharmacol Exp Ther. 1990;253:1103-1108.
7. Williams RE, Zweier JL, Flaherty JT. Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts. Circulation. 1991;83:1006-1014.
8. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest. 1984;74:1890-1894.
9. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by contents of human atherosclerotic lesions. Biochem J. 1992;286:901-905.
10. Yuan X-M, Brunk UT, Olsson AG. Effects of iron-and hemoglobin-loaded human monocyte-derived macrophages on oxidation and uptake of LDL. Arterioscler Thromb Vasc Biol. 1995;15:1345-1351.
11. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff memorial lecture. Arterioscler Thromb Vasc Biol. 1996;16:831-842.
12. Salonen JT, Nyyssöen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86:803-811.
13. Berge LN, Bonaa KH, Nordoy A. Serum ferritin, sex hormones, and cardiovascular risk factors in healthy women. Arterioscler Thromb. 1994; 14:857-861.
14. Kiechl S, Aichner F, Gerstenbrand F, Egger G, Mair A, Rungger G, Spögler F, Jarosch E, Oberhollenzer F, Willeit J. Body iron stores and presence of carotid atherosclerosis: results from the Bruneck study. Arterioscler Thromb. 1994;14:1625-1630.
15. Morrison HI, Semenciw RM, Mao Y, Wigle DT. Serum iron and risk of fatal acute myocardial infarction. Epidemiology. 1994;5:243-246.
16. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation. 1997;96:3300-3307.
17. Reunanen A, Takkunen H, Knekt P. Seppänen R, Aromaa A. Body iron stores, dietary iron intake and coronary heart disease mortality. J Intern Med. 1995;238:223-230.
18. Ascherio A. Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ. Dietary iron intake and risk of coronary disease among men. Circulation. 1994;89:969-974.
19. Magnusson MK, Sigfusson G, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation. 1994;89:102-108.
20. Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation. 1994;89:2915-2918.
21. Aronow WS. Serum ferritin is not a risk factor for coronary artery disease in men and women ages >62 years. Am J Cardiol. 1993;72:347-348.
22. Regnstrom J, Tomvall P, Kallner A, Nilsson J, Hamsten A. Stored iron levels and myocardial infarction at young age. Atherosclerosis. 1994;106: 123-125.
23. Moore M, Folsom AR, Barnes RW, Eckfeldt JH. No association between serum ferritin and asymptomatic carotid atherosclerosis. Am J Epidemiol. 1995;141:719-723.
24. Pang J-HS, Jiang M-J, Chen Y-L, Wang F-W, Wang DL, Chu S-H, Chau L-Y. Increased ferritin gene expression in atherosclerotic lesions. J Clin Invest. 1996;97:2204-2212.
25. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apoE: evaluation of lesional development and progression. Arterioscler Thromb. 1994;14:141-147.
26. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
27. McGowan SE, Henley SA. Iron and ferritin contents and distribution in human alveolar macrophages. J Lab Clin Med. 1988;1111:611-617.
28. Esterbauer H, Gebicki J. Puhl H, Jurgen G. The role of lipid peroxidation and antioxidant in oxidative modification of LDL. Free Radic Biol Med. 1992;13:341-390.
29. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Soeher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10:325-335.
30. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA. 1995;92:821-825.
31. Lalonde RG, Holbein BE. Role of iron in Trypanosoma cruzi infection of mice. J Clin Invest. 1984;73:470-476.
32. Salonen JT, Korpela H, Hyyssönen K, Porkkala E, Tuomainen TP, Belcher JD, Jacobs DR, Salonen R. Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: a randomized cross-over trial in male smokers. J Intern Med. 1995;237: 161-168.
33. Qiao J-H, Xie P-Z, Fishbein MC, Kreuzer J, Drake TA, Demer LL. Lusis AJ. Pathology of atheromatous lesions in inbred and genetically engineered mice: genetic determination of arterial calcification. Arterioscler Thromb. 1994;14:1480-1497.
34. Araujo JA, Romano EL, Brito BE, Parthé V, Romano M, Bracho M, Montano RF, Cardier J. Iron overload augments the development of atherosclerotic lesions in rabbit. Arterioscler Thromb Vasc Biol. 1995; 15:1172-1180.
35. Van Lenten BJ, Prieve J, Navab M, Hama S, Lusis AJ, Fogelman AM. Lipid-induced changes in intracellular iron nomeostasis in vitro and in vivo. J Clin Invest. 1995;95:2104-2110.
36. Porreca E, Ucchino S, Di Febbo C, Di Bartolomeo N, Angelucci D, Napolitano AM, Mezzetti A, Cuccurullo F. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb. 1994;14:299-304.